280. Huge arteriovenous malformation with cervicofacial or limb lesion
22 clinical trials,   26 drugs   (DrugBank: 13 drugs),   11 drug target genes,   147 drug target pathways

Searched query = "Huge arteriovenous malformation with cervicofacial or limb lesion", "Huge arteriovenous malformation", "Arteriovenous malformation"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04297033
(ClinicalTrials.gov)
January 1, 202121/2/2020Lovastatin for Treatment of Brain Arteriovenous MalformationsLovastatin for Treatment of Brain Arteriovenous Malformations:a Double-blind, Placebo-controlled Randomized TrialCerebral Arteriovenous MalformationDrug: Lovastatin;Drug: PlaceboBeijing Tiantan HospitalNULLNot yet recruiting18 YearsN/AAll1244Phase 2China
2ChiCTR2000036597
2020-10-012020-08-24The safety and efficacy of embolization of jaw arteriovenous malformations: one center observational studyThe safety and efficacy of embolization of jaw arteriovenous malformations: one center observational study jaw arteriovenous malformationsgroup of bleeding:coils and absolute ethanol;group of no bleeding:coils and absolute ethanol;Shanghai Ninth People Hospital, School of Medicine, Shanghai Jiaotong UniversityNULLPending515Bothgroup of bleeding:30;group of no bleeding:30;N/AChina
3ChiCTR2000036576
2020-09-012020-08-24A randomized controlled trial for comparing the effect and outcomes with different embolic agent: Absolute Ethanol and Onyx in the treatment of AVMA randomized controlled trial for comparing the effect and outcomes with different embolic agent: Absolute Ethanol and Onyx in the treatment of AVM arteriovenous malformationsGroup 1:absolute ethanol;Group 2:Oynx;Shanghai Ninth People Hospital, School of Medicine, Shanghai Jiaotong UniversityNULLRecruitingBothGroup 1:30;Group 2:30;N/AChina
4EUCTR2019-001530-33-FR
(EUCTR)
29/06/201901/04/2019TOPical sirolimus in linGUal microkystic lymphatic malformation-TOPGUNTOPical sirolimus in linGUal microkystic lymphatic malformation-TOPGUN - TOPGUN Lingual microcystic lymphatic malformations (LMLM) in children and adults
MedDRA version: 20.0;Level: LLT;Classification code 10003229;Term: Arteriovenous malformations;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
CHRU TOURSNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
12Phase 2France
5ChiCTR1900021901
2019-03-202019-03-15Efficacy and Safety of Thalidomide for the Treatment of Arteriovenous Malformations in Central Nervous System: Pilot StudyEfficacy and Safety of Thalidomide for the Treatment of Arteriovenous Malformations in Central Nervous System: Pilot Study central nervous system arteriovenous malformationsCase series:Oral thalidomide;Xuanwu Hospital, Capital Medical UniversityNULLCompletedBothCase series:30;China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2018-001359-11-FR
(EUCTR)
22/02/201923/07/20180.1% topical sirolimus in the treatment of cutaneous microcystic lymphatic malformations in children and adults: phase II, split-body randomized, double-blind, vehicle-controlled clinical trial0.1% topical sirolimus in the treatment of cutaneous microcystic lymphatic malformations in children and adults: phase II, split-body randomized, double-blind, vehicle-controlled clinical trial - TOPICAL Cutaneous microcystic lymphatic malformations (CMLM) in children and adults
MedDRA version: 20.0;Level: LLT;Classification code 10003229;Term: Arteriovenous malformations;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
CHRU TOURSNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
55Phase 2France
7ChiCTR1800017616
2018-08-062018-08-06A randomized controlled trial for comparing the effect and outcomes with different embolic agent: Absolute ethanol, Onyx and n-BCA in the treatment of AVMA randomized controlled trial for comparing the effect and outcomes with different embolic agent: Absolute ethanol, Onyx and n-BCA in the treatment of AVM arteriovenous malformationsEthanol group:Embolization with ethanol;Onyx group:Embolization with Onyx;n-BCA group:Embolization with n-BCA;Shanghai 9th People's Hospital, Shanghai Jiaotong University School of MedicineNULLRecruitingBothEthanol group:30;Onyx group:30;n-BCA group:30;China
8ChiCTR1800015220
2018-03-142018-03-15Prospective evaluation of embolization with absolute alcohol in the treatment of arteriovenous malformationsProspective evaluation of embolization with absolute alcohol in the treatment of arteriovenous malformations arteriovenous malformationsEthanol group:Embolization with absolute ethanol;Shanghai 9th People's Hospital, Shanghai Jiaotong University School of MedicineNULLRecruitingBothEthanol group:30;China
9NCT02625389
(ClinicalTrials.gov)
November 29, 20173/12/2015Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization.Safety and Efficacy of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. A Phase IV Study.Congenital Hemangioma;Hemangioendothelioma;Angiosarcoma;Arteriovenous MalformationDrug: Lipiodol® Ultra Fluid with surgical gluesGuerbetNULLRecruiting18 YearsN/AAll125Phase 4India
10JPRN-UMIN000030522
2017/11/1422/12/2017A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomalies Intractable vascular anomalies: Cystic lymphatic malformation, Lymphangiomatosis (Generalized lymphatic anomaly, Kaposiform lymphangiomatosis), Gorham-Stout disease, Kaposiform hemangioendothelioma and Tuffted angioma with Kasabach-Merritt phenomenon, Nenous malformation, Arteriovenous malformation, Klippel-Trenaunay-Weber syndrome,Bluerubber bleb nevus syndrome, Complex-combined vascular malformationsBody surface area (BSA) >= 1.0m2: an initial dose of sirolimus (2mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day.
BSA < 1.0m2: an initial dose of sirolimus (1mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day.
Gifu UniversityNULLRecruitingNot applicableNot applicableMale and Female50Not selectedJapan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT03306836
(ClinicalTrials.gov)
September 201631/5/2017Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2Multi-center,Single Blind,Prospective Randomized Controlled Trial of Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid OperationCerebral Aneurysm;Arteriovenous MalformationsDrug: Heparin SodiumBeijing Tiantan HospitalTang-Du Hospital;Kunming Medical University;First Affiliated Hospital of Fujian Medical University;Nanjing PLA General Hospital;Fujian Medical University Union HospitalRecruitingN/A70 YearsAll408N/AChina
12NCT02314377
(ClinicalTrials.gov)
June 201625/11/2014Bevacizumab Therapy for Brain Arteriovenous MalformationBevacizumab Therapy for Brain Arteriovenous MalformationBrain Arteriovenous MalformationDrug: BevacizumabUniversity of California, San FranciscoNULLCompleted18 Years64 YearsAll2Phase 1United States
13ChiCTR-IOR-16008047
2016-03-012016-03-03Early intervention of extracranial arteriovenous malformations with bleomycin: a prospective, multicenter, single-blind, randomized, controlled clinical trialEarly intervention of extracranial arteriovenous malformations with bleomycin: a prospective, multicenter, single-blind, randomized, controlled clinical trial extracranial arteriovenous malformationsbleomycin group:Intralesional Bleomycin Injection;Control group:No medicine;Shanghai 9th People's Hospital, Shanghai Jiaotong University School of MedicineNULLRecruitingBothbleomycin group:80;Control group:40;China
14NCT03076099
(ClinicalTrials.gov)
January 1, 20166/3/2017Dexmedetomidine on Post-operative Blood Pressure in Bain Arteriovenous Malformation EmbolizationEffects of Dexmedetomidine on Post-operative Blood Pressure in Patients Undergoing Brain Arteriovenous Malformation EmbolizationAnesthesiaDrug: Dexmedetomidine;Other: normal salineNan JiangNULLRecruiting18 Years65 YearsAll30N/AChina
15NCT02552459
(ClinicalTrials.gov)
September 201526/5/2015Effect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in NeurosurgeryEffect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in Neurosurgery: A Randomized Controlled StudyArteriovenous MalformationDrug: Sufentanil;Drug: dexmedetomidine 1;Drug: dexmedetomidine 2;Drug: dexmedetomidine 3First Affiliated Hospital, Sun Yat-Sen UniversityNULLRecruiting18 Years65 YearsBoth120Phase 4China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT02042326
(ClinicalTrials.gov)
September 12, 201420/1/2014Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous MalformationsProspective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous MalformationsArteriovenous MalformationsDrug: SirolimusCentre Hospitalier Universitaire, AmiensNULLRecruiting2 YearsN/AAll50Phase 2Belgium;France
17ChiCTR-OOB-15007258
2014-03-102015-10-23Early Intervention of Extracranial Arteriovenous Malformations with intralesional bleomycin injections: A Prospective StudyEarly Intervention of Extracranial Arteriovenous Malformations with intralesional bleomycin injections: A Prospective Study Arteriovenous Malformationbleomycin group:intralesional adminstrated bleomycin ;Shanghai 9th People's Hospital, Shanghai Jiaotong University School of MedicineNULLRecruiting260Bothbleomycin group:30;China
18NCT02496013
(ClinicalTrials.gov)
January 20146/7/2015Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEBRadiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Diagnostic Performance of 68Ga-NEB in Healthy Volunteers and Patients With Hepatic Space-occupying Lesions and Suspicious Lymph Nodes MetastasisArteriovenous Malformation;Hemangioma;Neoplasms Lymph Nodes;LymphedemaDrug: 68Ga-NEBPeking Union Medical College HospitalNational Institute for Biomedical Imaging and Bioengineering (NIBIB)Recruiting18 YearsN/AAll70Phase 1China
19NCT00783523
(ClinicalTrials.gov)
March 200830/10/2008Influence of MMP on Brain AVM HemorrhageInfluence of Matrix Metalloproteinase on Brain Arteriovenous Malformation HemorrhageArteriovenous Malformations;Cavernous Angiomas;Brain AneurysmsDrug: Doxycycline or PlaceboUniversity of California, San FranciscoNULLCompleted13 YearsN/ABoth33Phase 1United States
20NCT00389935
(ClinicalTrials.gov)
October 200617/10/2006Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal BleedingThalidomide Reduces Arteriovenous Malformation Related Gastrointestinal BleedingArteriovenous Malformation;Hereditary Hemorrhagic Telangiectasia;Hematochezia;MelenaDrug: ThalidomideNorthport Veterans Affairs Medical CenterGeorgia Regents University;University of Massachusetts, WorcesterCompleted18 YearsN/ABoth14Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT00243893
(ClinicalTrials.gov)
July 200424/10/2005Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and AneurysmsTetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and AneurysmsAneurysms;Arteriovenous MalformationsDrug: minocycline;Drug: doxycyclineUniversity of California, San FranciscoNational Institute of Neurological Disorders and Stroke (NINDS)Completed13 Years80 YearsBoth26Phase 1United States
22EUCTR2019-003573-26-BE
(EUCTR)
18/12/2019Evaluating the safety and efficacy of Trametinib in Arterio-Venous Malformations that are refractory to standard careMonocentric pilot trial evaluating efficacy of Trametinib in Arteriovenous Malformations that are refractory to standard treatments or for which standard treatment are contra-indicated - TRAMAV Arteriovenous Malformations that are refractory to standard treatments or for which standard treatment are contra-indicated;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Trade Name: Mekinist
Product Name: Mekinist
Cliniques universitaires Saint-LucNULLNAFemale: yes
Male: yes
20Phase 2Belgium